OCX - OncoCyte Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
1.8900
-0.1000 (-5.03%)
As of 3:52PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.9900
Open1.9800
Bid1.9000 x 2200
Ask1.9200 x 1000
Day's Range1.8900 - 1.9500
52 Week Range1.1650 - 6.9200
Volume310,760
Avg. Volume355,055
Market Cap98.229M
Beta (3Y Monthly)5.24
PE Ratio (TTM)N/A
EPS (TTM)-0.3810
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.15
Trade prices are not sourced from all markets
  • ACCESSWIRE12 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OncoCyte Corporation - OCX

    NEW YORK, NY / ACCESSWIRE / July 11, 2019 / Pomerantz LLP is investigating claims on behalf of investors of OncoCyte Corporation (“OncoCyte” or the “Company”) (NYSEAMERICAN: OCX). Such investors are advised ...

  • Is OncoCyte Corporation (NYSEMKT:OCX) Trading At A 47% Discount?
    Simply Wall St.12 days ago

    Is OncoCyte Corporation (NYSEMKT:OCX) Trading At A 47% Discount?

    Does the July share price for OncoCyte Corporation (NYSEMKT:OCX) reflect what it's really worth? Today, we will...

  • GuruFocus.com16 days ago

    Insiders Roundup: OncoCyte, BioSciences

    Largest insider trades of the week

  • ACCESSWIRE21 days ago

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of OncoCyte Corporation (OCX)

    NEW YORK, NY / ACCESSWIRE / July 2, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of OncoCyte Corporation ("OncoCyte" or the "Company") ...

  • GlobeNewswire27 days ago

    OncoCyte Provides Mid-Year Update

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year update and announced that the Company will require additional time to complete its ongoing CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer. In the CLIA Validation Study, started in late April, OncoCyte is assaying approximately 120 samples previously tested in its R&D Validation study, with the goal of demonstrating that the same results can be obtained in the Company’s CLIA-validated laboratory.

  • Benzingalast month

    The Companies Set To Join The Russell Index July 1

    OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...

  • Markitlast month

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    OncoCyte Corp NYSE MKT:OCXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for OCX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting OCX. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding OCX are favorable, with net inflows of $521 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswirelast month

    OncoCyte to be Added to the Russell 2000®, 3000® and Microcap Indexes

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the company will be added to the Russell 2000®, Russell 3000® and Russell Microcap Indexes, effective when the U.S. markets open on July 1, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index. “We are pleased to be joining these three Russell indexes,” commented William Annett, President and CEO of OncoCyte.

  • GlobeNewswire2 months ago

    OncoCyte Announces Chief Executive Officer Transition

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that diagnostics industry veteran and current Board member Ronald Andrews will assume the role of Chief Executive Officer, effective July 1. Mr. Andrews brings to OncoCyte over 30 years of diverse experience in the clinical and molecular diagnostics field, with a particular focus on oncology.

  • GlobeNewswire2 months ago

    OncoCyte Announces Participation at the 2019 BIO International Convention

    ALAMEDA, Calif., May 29, 2019 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that.

  • GlobeNewswire2 months ago

    OncoCyte Strengthens Senior Management Team With Two New Hires

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced the appointment of Padma Sundar, an industry leader in oncology diagnostics strategy and marketing, as Senior Vice President of Marketing and Market Access, effective May 22, 2019. The Company also announced the appointment of Dr. Kim Dickinson, a recognized leader in clinical operations and pathology, as Vice President of Clinical Operations, effective May 28, 2019.

  • GlobeNewswire2 months ago

    OncoCyte Presents Positive Results from R&D Validation Study of DetermaVu™ at the American Thoracic Society 2019 International Conference

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today presented results from the Company’s R&D Validation study at the American Thoracic Society (ATS) 2019 International Conference, which is being held May 17 to May 22 in Dallas. The poster details the compelling results from the Company’s successful R&D Validation study of DetermaVu™, OncoCyte’s liquid biopsy test for the early detection of lung cancer.

  • OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%
    Zacks2 months ago

    OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%

    OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • OncoCyte Corporation (OCX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    OncoCyte Corporation (OCX) Q1 2019 Earnings Call Transcript

    OCX earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    OncoCyte: 1Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had a loss of 8 cents. In the final minutes of trading on Tuesday, the company's shares hit $4.31. A year ago, they were trading at $2.40. ...

  • GlobeNewswire2 months ago

    OncoCyte Provides Corporate Update and Reports First Quarter 2019 Financial Results

    Completes successful Analytical Validation study and initiates CLIA Validation study On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at.

  • ACCESSWIRE2 months ago

    OncoCyte Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2019 / OncoCyte Corp. (NYSEMKT: OCX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern Time. ...

  • GlobeNewswire2 months ago

    OncoCyte to Report First Quarter 2019 Financial Results on Tuesday, May 14

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter ended March 31, 2019, on Tuesday, May 14, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 14, 2019 at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments. To access the live webcast, go to the investor relations section on the Company’s website, http://investors.oncocyte.com/events-and-presentations.

  • GlobeNewswire3 months ago

    OncoCyte Announces Successful Completion of Analytical Validation Study and Commencement of CLIA Validation Study

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the successful completion of the Company’s Analytical Validation study and the commencement of a CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer. The Analytical Validation Study was designed to establish performance characteristics of the ThermoFisher Next-Generation Sequencing assay system in OncoCyte’s Clinical Laboratory.

  • The OncoCyte (NYSEMKT:OCX) Share Price Has Gained 106%, So Why Not Pay It Some Attention?
    Simply Wall St.3 months ago

    The OncoCyte (NYSEMKT:OCX) Share Price Has Gained 106%, So Why Not Pay It Some Attention?

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right business to buy shares in, you can make more than you can lose. For example, the OncoCyte Corporation (NYSE...

  • Associated Press4 months ago

    OncoCyte: 4Q Earnings Snapshot

    The Alameda, California-based company said it had a loss of 11 cents per share. For the year, the company reported that its loss narrowed to $15.8 million, or 42 cents per share. In the final minutes of ...